GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Equity-to-Asset

Nautilus Biotechnology (Nautilus Biotechnology) Equity-to-Asset : 0.86 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Nautilus Biotechnology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $249.49 Mil. Nautilus Biotechnology's Total Assets for the quarter that ended in Mar. 2024 was $288.65 Mil.

The historical rank and industry rank for Nautilus Biotechnology's Equity-to-Asset or its related term are showing as below:

NAUT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35   Med: 0.9   Max: 0.99
Current: 0.86

During the past 4 years, the highest Equity to Asset Ratio of Nautilus Biotechnology was 0.99. The lowest was -0.35. And the median was 0.90.

NAUT's Equity-to-Asset is ranked better than
77.36% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs NAUT: 0.86

Nautilus Biotechnology Equity-to-Asset Historical Data

The historical data trend for Nautilus Biotechnology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nautilus Biotechnology Equity-to-Asset Chart

Nautilus Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-0.35 0.91 0.90 0.87

Nautilus Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.88 0.87 0.87 0.86

Competitive Comparison of Nautilus Biotechnology's Equity-to-Asset

For the Biotechnology subindustry, Nautilus Biotechnology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nautilus Biotechnology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's Equity-to-Asset falls into.



Nautilus Biotechnology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Nautilus Biotechnology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=265.353/305.565
=

Nautilus Biotechnology's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=249.492/288.65
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nautilus Biotechnology  (NAS:NAUT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Nautilus Biotechnology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nautilus Biotechnology (Nautilus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
2701 Eastlake Avenue East, Seattle, WA, USA, 98102
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Executives
Michael Seth Altman director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar officer: Senior VP, Product Development C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld officer: Chief People Officer C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry officer: CFO and Treasurer C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy officer: General Counsel C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Sujal M Patel director, 10 percent owner, officer: CEO, President, and Secretary C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin officer: Senior VP, Operations 3101 WESTERN AVENUE, SEATTLE WA 98121
Karen Akinsanya director SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain director 1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Benjamin A Horowitz 10 percent owner 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Marc L Andreessen 10 percent owner C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111